BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to HCT116 cell line is 459
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs and SFA followed by qRT-PCR and Western Blotting | NA | 0.6 | 0.7582 | 35155201 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and FACs followed by RT-PCR and Western Blotting | NA | 0.6 | 0.7582 | 21750907 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | qRT-PCR followed by Western Blotting and SFA | NA | 0.6 | 0.7582 | 30912138 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR followed by Western Blotting and SFA | NA | 0.6 | 0.7582 | 21596996 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil | SFA followed by Western Blotting and qRT-PCR | NA | 0.6 | 0.7582 | 28990068 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA and Western Blotting | NA | 0.6 | 0.7582 | 34798428 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by Western Blotting | NA | 0.6 | 0.7582 | 21123622 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by Western Blotting | NA | 0.6 | 0.7582 | 22623141 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by Western Blotting | NA | 0.6 | 0.7582 | 29928431 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | MACs followed by SFA and Western Blotting | NA | 0.6 | 0.7582 | 27894099 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting and FACs | NA | 0.6 | 0.7582 | 26124007 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | Western Blotting followed by FACs and Tumorigenicity assay | NA | 0.6 | 0.7582 | 20023382 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs and SFA followed by IF staining | NA | 0.6 | 0.7582 | 33819194 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | MACs and IHC staining | NA | 0.6 | 0.7582 | 31390540 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by IF staining and FACs | NA | 0.6 | 0.7582 | 22745705 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by CFA and SFA and qRT-PCR | NA | 0.6 | 0.7582 | 35392530 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs and qRT-PCR | NA | 0.6 | 0.7582 | 35242031 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs and RT-PCR followed by CFA | NA | 0.6 | 0.7582 | 26840024 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by RT-PCR | NA | 0.6 | 0.7582 | 30788057 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA and qRT-PCR | NA | 0.6 | 0.7582 | 29307822 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil+Oxaliplatin | RT-PCR followed by FACs | NA | 0.6 | 0.7582 | 21774804 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.7582 | 27997180 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.6 | 0.7582 | 29354056 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | Western Blotting | NA | 0.6 | 0.7582 | 22319203 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and IF staining | NA | 0.6 | 0.7582 | 24039918 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by IF staining | NA | 0.6 | 0.7582 | 28188489 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by IHC staining | NA | 0.6 | 0.7582 | 22487097 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by IHC staining | NA | 0.6 | 0.7582 | 22487097 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | Docetaxel | qRT-PCR | NA | 0.6 | 0.7582 | 27748801 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR | NA | 0.6 | 0.7582 | 22871210 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR | NA | 0.6 | 0.7582 | 29902974 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR followed by SFA | NA | 0.6 | 0.7582 | 32037723 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and qRT-PCR | NA | 0.6 | 0.7582 | 26241688 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR | NA | 0.6 | 0.7582 | 31544978 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil | FACs | NA | 0.6 | 0.7582 | 34151658 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by CFA | NA | 0.6 | 0.7582 | 33958701 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA | NA | 0.6 | 0.7582 | 34815662 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 35116403 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.6 | 0.7582 | 19734943 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil+Oxaliplatin | FACs | NA | 0.6 | 0.7582 | 19956394 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.6 | 0.7582 | 20433742 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.6 | 0.7582 | 20711432 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.6 | 0.7582 | 22842824 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.6 | 0.7582 | 24122993 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.6 | 0.7582 | 24760019 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.6 | 0.7582 | 25154976 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.6 | 0.7582 | 25941936 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.6 | 0.7582 | 29740695 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.6 | 0.7582 | 30429213 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.6 | 0.7582 | 31812723 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.6 | 0.7582 | 32729895 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs and CFA | NA | 0.6 | 0.7582 | 25154976 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs and SFA | NA | 0.6 | 0.7582 | 21694723 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs and Tumorigenicity assay | NA | 0.6 | 0.7582 | 21826669 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA | NA | 0.6 | 0.7582 | 22329848 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA | NA | 0.6 | 0.7582 | 26745821 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA | NA | 0.6 | 0.7582 | 27455311 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA | NA | 0.6 | 0.7582 | 31950022 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA and Tumorigenicity assay | NA | 0.6 | 0.7582 | 19451087 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA and Tumorigenicity assay | NA | 0.6 | 0.7582 | 22074823 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA and Tumorigenicity assay | NA | 0.6 | 0.7582 | 31120140 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by Tumorigenicity assay and SFA | NA | 0.6 | 0.7582 | 21454414 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | MACs and SFA followed by CFA and Tumorigenicity assay | NA | 0.6 | 0.7582 | 27600678 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and FACs | NA | 0.6 | 0.7582 | 25804133 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and FACs | NA | 0.6 | 0.7582 | 26399781 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 20630067 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 23345327 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 26506839 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 28825721 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs | NA | 0.6 | 0.7582 | 31883392 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.6 | 0.7582 | 19737148 |
| PROM1 | 9454 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SP assay followed by FACs | NA | 0.6 | 0.7582 | 21720213 |
| SOX2 | 11195 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by PCR array assay | NA | 0.48 | 0.5695 | 20630067 |
| ABCG2 | 74 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.1739 | 35155201 |
| ABCG2 | 74 | LTM | Colon Cancer | Carcinoma | HCT116 | Oxaliplatin | SFA followed by Western Blotting | NA | 0.48 | 0.1739 | 24330852 |
| ABCG2 | 74 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil+Oxaliplatin | Western Blotting followed by SFA | NA | 0.48 | 0.1739 | 21161336 |
| ABCG2 | 74 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR | NA | 0.48 | 0.1739 | 26206183 |
| ABCG2 | 74 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qPCR | NA | 0.48 | 0.1739 | 28825721 |
| ABCG2 | 74 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.1739 | 21750907 |
| AKR1C1 | 384 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0085 | 35155201 |
| ALCAM | 400 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR followed by Western Blotting and SFA | NA | 0.48 | 0.0583 | 21596996 |
| ALCAM | 400 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil+Oxaliplatin | FACs followed by RT-PCR | NA | 0.48 | 0.0583 | 19956394 |
| ALCAM | 400 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil+Oxaliplatin | SFA followed by Western Blotting | NA | 0.48 | 0.0583 | 22761031 |
| ALCAM | 400 | LTM | Colon Cancer | Carcinoma | HCT116 | Docetaxel | qRT-PCR | NA | 0.48 | 0.0583 | 27748801 |
| ALCAM | 400 | LTM | Colon Cancer | Carcinoma | HCT116 | Docetaxel | qRT-PCR | NA | 0.48 | 0.0583 | 27748801 |
| ALCAM | 400 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil+Oxaliplatin | qRT-PCR and SFA | NA | 0.48 | 0.0583 | 21161336 |
| ALCAM | 400 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil+Oxaliplatin | RT-PCR | NA | 0.48 | 0.0583 | 21774804 |
| ALCAM | 400 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qPCR | NA | 0.48 | 0.0583 | 26506839 |
| ALCAM | 400 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA and Tumorigenicity assay | NA | 0.48 | 0.0583 | 19451087 |
| ALCAM | 400 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and FACs | NA | 0.48 | 0.0583 | 25804133 |
| ALCAM | 400 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs | NA | 0.48 | 0.0583 | 23345327 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | qRT-PCR followed by Western Blotting and SFA | NA | 0.48 | 0.684 | 30912138 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.684 | 32037723 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR followed by Western Blotting and SFA | NA | 0.48 | 0.684 | 21596996 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qPCR and ALDEFLUOR assay | NA | 0.48 | 0.684 | 31349708 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by RT-PCR and ALDEFLUOR assay | NA | 0.48 | 0.684 | 30774996 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.684 | 26785732 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.684 | 27997180 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | ALDEFLUOR assay followed by FACs and SFA | NA | 0.48 | 0.684 | 21694723 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | IHC staining | NA | 0.48 | 0.684 | 31810923 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.684 | 35242031 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.684 | 35392530 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR | NA | 0.48 | 0.684 | 29902974 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR followed by CFA | NA | 0.48 | 0.684 | 26840024 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | ALDEFLUOR assay | NA | 0.48 | 0.684 | 19923910 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | Paclitaxel | ALDEFLUOR assay | NA | 0.48 | 0.684 | 23327190 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | ALDEFLUOR assay | NA | 0.48 | 0.684 | 24122993 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | ALDEFLUOR assay followed by SFA and Tumorigenicity assay | NA | 0.48 | 0.684 | 22074823 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs and CFA | NA | 0.48 | 0.684 | 25154976 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs and CFA | NA | 0.48 | 0.684 | 25154976 |
| ALDH1A1 | 402 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SP assay followed by ALDEFLUOR assay | NA | 0.48 | 0.684 | 21720213 |
| BMI1 | 1066 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.1135 | 28990068 |
| BMI1 | 1066 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.1135 | 27997180 |
| BMI1 | 1066 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.1135 | 32066912 |
| BMI1 | 1066 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.1135 | 23174018 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | qRT-PCR followed by Western Blotting and SFA | NA | 0.48 | 1 | 30912138 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR followed by Western Blotting and SFA | NA | 0.48 | 1 | 21596996 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 1 | 28990068 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 1 | 31544978 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs and SFA followed by IF staining | NA | 0.48 | 1 | 33819194 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by IF staining and FACs | NA | 0.48 | 1 | 22745705 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by CFA and SFA and qRT-PCR | NA | 0.48 | 1 | 35392530 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs and qRT-PCR | NA | 0.48 | 1 | 35242031 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs and RT-PCR followed by CFA | NA | 0.48 | 1 | 26840024 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil+Oxaliplatin | FACs followed by RT-PCR | NA | 0.48 | 1 | 19956394 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by RT-PCR | NA | 0.48 | 1 | 30788057 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR and FACs followed by SFA | NA | 0.48 | 1 | 32066912 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil+Oxaliplatin | RT-PCR followed by FACs | NA | 0.48 | 1 | 21774804 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and FACs followed by RT-PCR | NA | 0.48 | 1 | 21750907 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs and qPCR | NA | 0.48 | 1 | 26506839 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil+Oxaliplatin | SFA followed by Western Blotting | NA | 0.48 | 1 | 22761031 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 26785732 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 27894099 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 29348560 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.48 | 1 | 29354056 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | Western Blotting | NA | 0.48 | 1 | 22319203 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil+Oxaliplatin | Western Blotting followed by SFA | NA | 0.48 | 1 | 22072622 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | IHC staining | NA | 0.48 | 1 | 31810923 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and IF staining | NA | 0.48 | 1 | 27207017 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil+Oxaliplatin | qRT-PCR and SFA | NA | 0.48 | 1 | 21161336 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR followed by SFA | NA | 0.48 | 1 | 32037723 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and qRT-PCR | NA | 0.48 | 1 | 25368233 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.48 | 1 | 33419797 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil | FACs | NA | 0.48 | 1 | 34151658 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by CFA | NA | 0.48 | 1 | 33958701 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | Paclitaxel | CFA followed by FACs | NA | 0.48 | 1 | 23624503 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.48 | 1 | 19734943 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.48 | 1 | 20433742 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.48 | 1 | 22842824 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.48 | 1 | 24760019 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.48 | 1 | 25154976 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.48 | 1 | 25154976 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.48 | 1 | 25941936 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.48 | 1 | 29740695 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.48 | 1 | 29928431 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.48 | 1 | 31641961 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.48 | 1 | 32729895 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA | NA | 0.48 | 1 | 21701559 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA | NA | 0.48 | 1 | 22329848 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA | NA | 0.48 | 1 | 27455311 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA | NA | 0.48 | 1 | 30451890 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA | NA | 0.48 | 1 | 31950022 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA | NA | 0.48 | 1 | 33209130 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA and Tumorigenicity assay | NA | 0.48 | 1 | 19451087 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA and Tumorigenicity assay | NA | 0.48 | 1 | 31120140 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by Tumorigenicity assay and SFA | NA | 0.48 | 1 | 21454414 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | MACs and SFA followed by CFA and Tumorigenicity assay | NA | 0.48 | 1 | 27600678 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and FACs | NA | 0.48 | 1 | 26399781 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and MACs | NA | 0.48 | 1 | 24696849 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs | NA | 0.48 | 1 | 20630067 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs | NA | 0.48 | 1 | 23345327 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs | NA | 0.48 | 1 | 23592893 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs | NA | 0.48 | 1 | 31883392 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.48 | 1 | 19737148 |
| CD44 | 1681 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil | SP assay followed by FACs | NA | 0.48 | 1 | 30005681 |
| EPCAM | 11529 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | qRT-PCR followed by Western Blotting and SFA | NA | 0.48 | 0.211 | 30912138 |
| EPCAM | 11529 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.211 | 27997180 |
| EPCAM | 11529 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | Western Blotting | NA | 0.48 | 0.211 | 29354056 |
| EPCAM | 11529 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | IHC staining | NA | 0.48 | 0.211 | 31810923 |
| EPCAM | 11529 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and qRT-PCR | NA | 0.48 | 0.211 | 25368233 |
| EPCAM | 11529 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.48 | 0.211 | 31641961 |
| EPCAM | 11529 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA | NA | 0.48 | 0.211 | 33209130 |
| EPCAM | 11529 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by Tumorigenicity assay and SFA | NA | 0.48 | 0.211 | 21454414 |
| EPCAM | 11529 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and FACs | NA | 0.48 | 0.211 | 25804133 |
| EPCAM | 11529 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs | NA | 0.48 | 0.211 | 26124007 |
| EPCAM | 11529 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.48 | 0.211 | 19737148 |
| GCLC | 4311 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0032 | 35155201 |
| KLF4 | 6348 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0891 | 35155201 |
| KLF4 | 6348 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA and RT-PCR | NA | 0.48 | 0.0891 | 31120140 |
| KLF4 | 6348 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.0891 | 27997180 |
| KLF4 | 6348 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.0891 | 32037723 |
| KLF4 | 6348 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.0891 | 31544978 |
| LGR5 | 4504 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | qRT-PCR followed by Western Blotting and SFA | NA | 0.48 | 0.0753 | 30912138 |
| LGR5 | 4504 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR and Western Blotting followed by SFA | NA | 0.48 | 0.0753 | 32037723 |
| LGR5 | 4504 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by IF staining and FACs | NA | 0.48 | 0.0753 | 22745705 |
| LGR5 | 4504 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA and qRT-PCR | NA | 0.48 | 0.0753 | 29307822 |
| LGR5 | 4504 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.0753 | 27894099 |
| LGR5 | 4504 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | Western Blotting | NA | 0.48 | 0.0753 | 29354056 |
| LGR5 | 4504 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and IF staining | NA | 0.48 | 0.0753 | 26745821 |
| LGR5 | 4504 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR | NA | 0.48 | 0.0753 | 29902974 |
| LGR5 | 4504 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR followed by CFA | NA | 0.48 | 0.0753 | 26840024 |
| LGR5 | 4504 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.0753 | 32066912 |
| LGR5 | 4504 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qPCR | NA | 0.48 | 0.0753 | 28825721 |
| LGR5 | 4504 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.48 | 0.0753 | 22925500 |
| LGR5 | 4504 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA | NA | 0.48 | 0.0753 | 22329848 |
| LGR5 | 4504 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and FACs | NA | 0.48 | 0.0753 | 24039918 |
| LGR5 | 4504 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs | NA | 0.48 | 0.0753 | 23345327 |
| MACsC1 | 30215 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.0042 | 28990068 |
| MME | 7154 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | qRT-PCR followed by Western Blotting and SFA | NA | 0.48 | 0.0053 | 30912138 |
| MME | 7154 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA | NA | 0.48 | 0.0053 | 22329848 |
| NANOG | 20857 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 30774996 |
| NANOG | 20857 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.5461 | 28990068 |
| NANOG | 20857 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA and RT-PCR | NA | 0.48 | 0.5461 | 31120140 |
| NANOG | 20857 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by SFA and Western Blotting | NA | 0.48 | 0.5461 | 33819194 |
| NANOG | 20857 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and Western Blotting | NA | 0.48 | 0.5461 | 27207017 |
| NANOG | 20857 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting and Tumorigenicity assay | NA | 0.48 | 0.5461 | 30305725 |
| NANOG | 20857 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 35242031 |
| NANOG | 20857 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | qRT-PCR | NA | 0.48 | 0.5461 | 29426374 |
| NANOG | 20857 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR | NA | 0.48 | 0.5461 | 29902974 |
| NANOG | 20857 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.5461 | 32037723 |
| NANOG | 20857 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and qRT-PCR | NA | 0.48 | 0.5461 | 25368233 |
| NANOG | 20857 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and qRT-PCR | NA | 0.48 | 0.5461 | 26241688 |
| NANOG | 20857 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and qRT-PCR | NA | 0.48 | 0.5461 | 33209130 |
| NANOG | 20857 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qPCR | NA | 0.48 | 0.5461 | 31349708 |
| NANOG | 20857 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 29307822 |
| NANOG | 20857 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 31544978 |
| NANOG | 20857 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5461 | 23174018 |
| NANOG | 20857 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.48 | 0.5461 | 31641961 |
| NFE2L2 | 7782 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0042 | 35155201 |
| NQO1 | 2874 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0042 | 35155201 |
| POU5F1 | 9221 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 30774996 |
| POU5F1 | 9221 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil | SFA followed by Western Blotting and qRT-PCR | NA | 0.48 | 0.6448 | 28990068 |
| POU5F1 | 9221 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA and RT-PCR | NA | 0.48 | 0.6448 | 19451087 |
| POU5F1 | 9221 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA and RT-PCR | NA | 0.48 | 0.6448 | 31120140 |
| POU5F1 | 9221 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by SFA and Western Blotting | NA | 0.48 | 0.6448 | 33819194 |
| POU5F1 | 9221 | LTM | Colon Cancer | Carcinoma | HCT116 | Oxaliplatin | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 24330852 |
| POU5F1 | 9221 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 27997180 |
| POU5F1 | 9221 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting and Tumorigenicity assay | NA | 0.48 | 0.6448 | 30305725 |
| POU5F1 | 9221 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and IF staining | NA | 0.48 | 0.6448 | 26745821 |
| POU5F1 | 9221 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 35242031 |
| POU5F1 | 9221 | LTM | Colon Cancer | Carcinoma | HCT116 | Docetaxel | qRT-PCR | NA | 0.48 | 0.6448 | 27748801 |
| POU5F1 | 9221 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | qRT-PCR | NA | 0.48 | 0.6448 | 29426374 |
| POU5F1 | 9221 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.6448 | 32037723 |
| POU5F1 | 9221 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and qRT-PCR | NA | 0.48 | 0.6448 | 25368233 |
| POU5F1 | 9221 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and qRT-PCR | NA | 0.48 | 0.6448 | 33209130 |
| POU5F1 | 9221 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 29307822 |
| POU5F1 | 9221 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 31544978 |
| POU5F1 | 9221 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.6448 | 21750907 |
| POU5F1 | 9221 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.48 | 0.6448 | 31641961 |
| PRX | 13797 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0011 | 34798428 |
| RSPO2 | 28583 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0011 | 27158331 |
| SOX2 | 11195 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by RT-PCR and Western Blotting | NA | 0.48 | 0.5695 | 30774996 |
| SOX2 | 11195 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by SFA and Western Blotting | NA | 0.48 | 0.5695 | 33819194 |
| SOX2 | 11195 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 35392530 |
| SOX2 | 11195 | LTM | Colon Cancer | Carcinoma | HCT116 | Oxaliplatin | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 24330852 |
| SOX2 | 11195 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5695 | 27997180 |
| SOX2 | 11195 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting and Tumorigenicity assay | NA | 0.48 | 0.5695 | 30305725 |
| SOX2 | 11195 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and IF staining | NA | 0.48 | 0.5695 | 26745821 |
| SOX2 | 11195 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 35242031 |
| SOX2 | 11195 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | qRT-PCR | NA | 0.48 | 0.5695 | 29426374 |
| SOX2 | 11195 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR followed by SFA | NA | 0.48 | 0.5695 | 32037723 |
| SOX2 | 11195 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and qRT-PCR | NA | 0.48 | 0.5695 | 33209130 |
| SOX2 | 11195 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qPCR | NA | 0.48 | 0.5695 | 31349708 |
| SOX2 | 11195 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5695 | 29307822 |
| SOX2 | 11195 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by RT-PCR | NA | 0.48 | 0.5695 | 21750907 |
| SOX2 | 11195 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.48 | 0.5695 | 31641961 |
| SRXN1 | 16132 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0032 | 34798428 |
| PRDX2 | 9353 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by Western Blotting and SFA and Tumorigenicity assay | NA | 0.4 | 0.0074 | 27894099 |
| PRDX2 | 9353 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by IF staining | NA | 0.4 | 0.0074 | 33819194 |
| NOTCH1 | 7881 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by PCR array assay | NA | 0.32 | 0.0477 | 20630067 |
| CD24 | 1645 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs and qRT-PCR | NA | 0.32 | 0.456 | 35242031 |
| CD24 | 1645 | LTM | Colon Cancer | Carcinoma | HCT116 | 5-Fluorouracil | FACs | NA | 0.32 | 0.456 | 34151658 |
| CD24 | 1645 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs | NA | 0.32 | 0.456 | 35116403 |
| CD24 | 1645 | LTM | Colon Cancer | Carcinoma | HCT116 | Paclitaxel | CFA followed by FACs | NA | 0.32 | 0.456 | 23624503 |
| CD24 | 1645 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.32 | 0.456 | 31641961 |
| CD24 | 1645 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA and Tumorigenicity assay | NA | 0.32 | 0.456 | 22329848 |
| CD24 | 1645 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and FACs | NA | 0.32 | 0.456 | 26399781 |
| CD24 | 1645 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and MACs | NA | 0.32 | 0.456 | 24696849 |
| MIR3120 | 38295 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA and qRT-PCR | NA | 0.32 | 0.0011 | 29307822 |
| NOTCH1 | 7881 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA and RT-PCR | NA | 0.32 | 0.0477 | 19451087 |
| NOTCH1 | 7881 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR | NA | 0.32 | 0.0477 | 35392530 |
| NOTCH1 | 7881 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qPCR | NA | 0.32 | 0.0477 | 26506839 |
| NR5A2 | 7984 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | qRT-PCR and FACs followed by SFA | NA | 0.32 | 0.0042 | 32037723 |
| SHH | 10848 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA and RT-PCR | NA | 0.32 | 0.0201 | 19451087 |
| WNT1 | 12774 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA and RT-PCR | NA | 0.32 | 0.0074 | 19451087 |
| IL8 | 6025 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.28 | 0.0159 | 19451087 |
| AKT1 | 391 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and Western Blotting | NA | 0.28 | 0.0074 | 26399781 |
| ALDH1A2 | 15472 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0117 | 29348560 |
| ALDH1A2 | 15472 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR followed by CFA | NA | 0.28 | 0.0117 | 26840024 |
| ALDH1A2 | 15472 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qPCR | NA | 0.28 | 0.0117 | 28825721 |
| BMP2 | 1069 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting and Migartion Invasion assay | NA | 0.28 | 0.0042 | 26124007 |
| CTNNB1 | 2514 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0647 | 35392530 |
| CTNNB1 | 2514 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and Western Blotting | NA | 0.28 | 0.0647 | 24039918 |
| CTNNB1 | 2514 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and Western Blotting | NA | 0.28 | 0.0647 | 24039918 |
| CTNNB1 | 2514 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qPCR | NA | 0.28 | 0.0647 | 31349708 |
| CXCR4 | 2561 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0498 | 27894099 |
| CXCR4 | 2561 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR | NA | 0.28 | 0.0498 | 22871210 |
| DCLK1 | 2700 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0159 | 26785732 |
| DCLK1 | 2700 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | Western Blotting | NA | 0.28 | 0.0159 | 22319203 |
| DPP4 | 3009 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | Western Blotting | NA | 0.28 | 0.0085 | 25884645 |
| DPP4 | 3009 | LTM | Colon Cancer | Carcinoma | HCT116 | Docetaxel | qRT-PCR | NA | 0.28 | 0.0085 | 27748801 |
| DPP4 | 3009 | LTM | Colon Cancer | Carcinoma | HCT116 | Docetaxel | qRT-PCR | NA | 0.28 | 0.0085 | 27748801 |
| IL8 | 6025 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0159 | 30305725 |
| PTEN | 9588 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and Western Blotting | Down | 0.28 | 0.0053 | 23894315 |
| SCD | 10571 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0127 | 33430034 |
| SNAI1 | 11128 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and Western Blotting | NA | 0.28 | 0.0212 | 24039918 |
| SNAI2 | 11094 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and Western Blotting | NA | 0.28 | 0.0159 | 24039918 |
| SOX9 | 11204 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | Western Blotting | NA | 0.28 | 0.0244 | 22319203 |
| NEUROG2 | 13805 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by PCR array assay | NA | 0.24 | 0.0021 | 20630067 |
| ALPI | 437 | HTM/LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0011 | 19451087 |
| ASCL2 | 739 | HTM/LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0053 | 19451087 |
| AXIN1 | 903 | HTM/LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0021 | 19451087 |
| BMP1 | 1067 | HTM/LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0032 | 19451087 |
| BMP3 | 1070 | HTM/LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0021 | 19451087 |
| BTRC | 1144 | HTM/LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0011 | 19451087 |
| CDC2 | 1722 | HTM/LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0042 | 19451087 |
| CTNNA1 | 2509 | HTM/LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0032 | 19451087 |
| EP300 | 3373 | HTM/LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0011 | 19451087 |
| FGF4 | 3682 | HTM/LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0011 | 19451087 |
| FGFR1 | 3688 | HTM/LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0053 | 19451087 |
| NEUROG2 | 13805 | HTM/LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0021 | 19451087 |
| PPARD | 9235 | HTM/LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0021 | 19451087 |
| S100B | 10500 | HTM/LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0021 | 19451087 |
| TNFRSF8 | 11923 | HTM/LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR | Up | 0.24 | 0.0021 | 19451087 |
| ASCL2 | 739 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR followed by SFA | NA | 0.24 | 0.0053 | 32037723 |
| ASCL2 | 739 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR | NA | 0.24 | 0.0053 | 31544978 |
| ABCB1 | 40 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR | NA | 0.2 | 0.0604 | 26206183 |
| ABCB1 | 40 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR | NA | 0.2 | 0.0604 | 29902974 |
| ABCC1 | 51 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR | NA | 0.2 | 0.0212 | 26206183 |
| EPHB2 | 3393 | LTM | Colon Cancer | Carcinoma | HCT116 | Docetaxel | qRT-PCR | NA | 0.2 | 0.0011 | 27748801 |
| GATA6 | 4174 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR and CFA | NA | 0.2 | 0.0021 | 31544978 |
| IL1B | 5992 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and RT-PCR followed by Migration assay | NA | 0.2 | 0.0074 | 23174018 |
| ITGB1 | 6153 | LTM | Colon Cancer | Carcinoma | HCT116 | Docetaxel | qRT-PCR | NA | 0.2 | 0.018 | 27748801 |
| ITGB1 | 6153 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs followed by SFA | NA | 0.2 | 0.018 | 22329848 |
| MIR21 | 31586 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0085 | 23894315 |
| MIR21 | 31586 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR and Tumorigenicity assay | NA | 0.2 | 0.0085 | 22072622 |
| MSI1 | 7330 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by RT-PCR and Tumorigenicity assay | NA | 0.2 | 0.0201 | 22925500 |
| MYC | 7553 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | RT-PCR followed by CFA | NA | 0.2 | 0.1304 | 26840024 |
| MYC | 7553 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA and qRT-PCR | NA | 0.2 | 0.1304 | 33209130 |
| NAMPT | 30092 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | qRT-PCR followed by SFA and CFA | NA | 0.2 | 0.0032 | 29203587 |
| SLC7A11 | 11059 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0021 | 34385181 |
| SLCO4A1 | 10953 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by qRT-PCR | NA | 0.2 | 0.0042 | 33958701 |
| CD24 | 1645 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs | NA | 0.12 | 0.456 | 30429213 |
| CD24 | 1645 | LTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by FACs | NA | 0.12 | 0.456 | 31883392 |
| ACTB | 132 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0021 | 22623141 |
| AKR1B1 | 381 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0032 | 22623141 |
| ANXA1 | 533 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0053 | 22623141 |
| ANXA3 | 541 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0085 | 22623141 |
| CDC42 | 1736 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0042 | 22623141 |
| CLIC1 | 2062 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0042 | 22623141 |
| CPOX | 2321 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0032 | 22623141 |
| EEF2 | 3214 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0053 | 22623141 |
| ENO1 | 3350 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0095 | 22623141 |
| ENO1 | 3350 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.08 | 0.0095 | 19451087 |
| EZR | 12691 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0064 | 22623141 |
| EZR | 12691 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0064 | 22623141 |
| EZR | 12691 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0064 | 22623141 |
| EZR | 12691 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0064 | 22623141 |
| FH | 3700 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0042 | 22623141 |
| HNRNPC | 5035 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0032 | 22623141 |
| HNRNPH3 | 5043 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0021 | 22623141 |
| HSP90AB1 | 5258 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0074 | 22623141 |
| HSP90AB1 | 5258 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.08 | 0.0074 | 19451087 |
| HSPA1A | 5232 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0053 | 22623141 |
| HSPA8 | 5241 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0085 | 22623141 |
| HSPB1 | 5246 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0053 | 22623141 |
| HSPD1 | 5261 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0064 | 22623141 |
| HSPD1 | 5261 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.08 | 0.0064 | 19451087 |
| HSPD1 | 5261 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.08 | 0.0064 | 19451087 |
| IMPDH2 | 6053 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0032 | 22623141 |
| KHSRP | 6316 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0032 | 22623141 |
| KRT18 | 6430 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0074 | 22623141 |
| KRT8 | 6446 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0074 | 22623141 |
| LMNA | 6636 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0042 | 22623141 |
| LMNA | 6636 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0042 | 22623141 |
| LMNA | 6636 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0042 | 22623141 |
| LMNA | 6636 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0042 | 22623141 |
| MDH1 | 6970 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0053 | 22623141 |
| PEBP1 | 8630 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0032 | 22623141 |
| PHGDH | 8923 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0032 | 22623141 |
| PPA1 | 9226 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0011 | 22623141 |
| PRDX1 | 9352 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0042 | 22623141 |
| PRDX4 | 17169 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0011 | 22623141 |
| PRDX6 | 16753 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0042 | 22623141 |
| PRTFDC1 | 23333 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0042 | 22623141 |
| SDHA | 10680 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0064 | 22623141 |
| SEPTIN2 | 7729 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0021 | 22623141 |
| STIP1 | 11387 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0042 | 22623141 |
| TALDO1 | 11559 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Up | 0.08 | 0.0032 | 22623141 |
| UGDH | 12525 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker followed by Proteomics | Down | 0.08 | 0.0053 | 22623141 |
| APP | 620 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 19451087 |
| BAX | 959 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 19451087 |
| BCL2L1 | 992 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19451087 |
| BCL3 | 998 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19451087 |
| BDNF | 1033 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 19451087 |
| BIRC3 | 591 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 19451087 |
| CASP2 | 1503 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 19451087 |
| CBX4 | 1554 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19451087 |
| CCAR1 | 24236 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19451087 |
| CCNG2 | 1593 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19451087 |
| CCPG1 | 24227 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19451087 |
| CD74 | 1697 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19451087 |
| CD74 | 1697 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19451087 |
| CDC25A | 1725 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19451087 |
| CDH11 | 1750 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 19451087 |
| CDK8 | 1779 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19451087 |
| CDV3 | 26928 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19451087 |
| CFL1 | 1874 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 19451087 |
| COX6A1 | 2277 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19451087 |
| CSNK1D | 2452 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19451087 |
| CXCL14 | 10640 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 19451087 |
| DCBLD2 | 24627 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 19451087 |
| DENR | 2769 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19451087 |
| DHCR24 | 2859 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 19451087 |
| EHF | 3246 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 19451087 |
| FBF1 | 24674 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19451087 |
| FOSB | 3797 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19451087 |
| FOXO3 | 3821 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19451087 |
| FXR1 | 4023 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19451087 |
| HSP90B1 | 12028 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 19451087 |
| HSP90B1 | 12028 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 19451087 |
| HSPA1B | 5233 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 19451087 |
| HSPA9 | 5244 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0042 | 20630067 |
| ID2 | 5361 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 19451087 |
| ID2B | 30656 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19451087 |
| IFI16 | 5395 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0042 | 19451087 |
| IGFBP3 | 5472 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0095 | 19451087 |
| IGFBP3 | 5472 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0095 | 19451087 |
| INSIG1 | 6083 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0053 | 19451087 |
| KAT7 | 17016 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0011 | 20630067 |
| KAT8 | 17933 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0011 | 20630067 |
| MACsF1 | 13664 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 19451087 |
| MAP3K2 | 6854 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 19451087 |
| MIB1 | 21086 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19451087 |
| MPHOSPH8 | 29810 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19451087 |
| MXD1 | 6761 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19451087 |
| NFKB1 | 7794 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 19451087 |
| NFKB2 | 7795 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19451087 |
| NFYC | 7806 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19451087 |
| NOTCH2 | 7882 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0117 | 20630067 |
| NPM1 | 7910 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 19451087 |
| PARD6A | 15943 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0032 | 20630067 |
| POSTN | 16953 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 19451087 |
| RAD21 | 9811 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0011 | 19451087 |
| RHOB | 668 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 19451087 |
| RHOB | 668 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 19451087 |
| SOCS2 | 19382 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0053 | 19451087 |
| SOX1 | 11189 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 19451087 |
| SOX1 | 11189 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | SFA followed by PCR array assay | NA | 0.04 | 0.0042 | 20630067 |
| SPARC | 11219 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 19451087 |
| TBX3 | 11602 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19451087 |
| TGFB1I1 | 11767 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0032 | 19451087 |
| TNFAIP3 | 11896 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0064 | 19451087 |
| TPM1 | 12010 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0042 | 19451087 |
| TRIB3 | 16228 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0011 | 19451087 |
| VDAC1 | 12669 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0021 | 19451087 |
| VEGFA | 12680 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.0032 | 19451087 |
| VIM | 12692 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Down | 0.04 | 0.017 | 19451087 |
| XIAP | 592 | HTM | Colon Cancer | Carcinoma | HCT116 | NA | FACs for CSC marker and SFA followed by Transcriptomics | Up | 0.04 | 0.0021 | 19451087 |